Examining bone development in children with type-1 diabetes
Canadian Bone Strength Development in Children With Type 1 Diabetes Study
This study looks at how bone development in children with type-1 diabetes compares to those without it to better understand their skeletal health as they grow.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 204 (estimated) |
| Ages | 10 Years to 12 Years |
| Sex | All |
| Sponsor | University of Saskatchewan Academic / other |
| Locations | 1 site (Saskatoon, Saskatchewan) |
| Trial ID | NCT06287840 on ClinicalTrials.gov |
What this trial studies
The Canadian Bone Strength Development Study aims to investigate the differences in bone development between children with type-1 diabetes (T1D) and those without. This observational study will involve 204 children, who will participate in four annual laboratory visits where various measurements related to bone strength, muscle strength, nutrition, and physical activity will be taken. The study will analyze how bone growth trajectories differ based on sex and the impact of body composition and physical activity on these differences. The findings could provide insights into the skeletal health of children with T1D during critical growth periods.
Who should consider this trial
Good fit: Ideal candidates include children aged 10-12 years with a diagnosis of type-1 diabetes for at least six months.
Not a fit: Patients with additional illnesses affecting bone health or those who have already experienced their adolescent growth spurt may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of bone health in children with type-1 diabetes.
How similar studies have performed: While there have been studies on bone health in diabetes, this specific approach focusing on developmental trajectories in children is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Children with Type-I Diabetes: Inclusion Criteria * Females: 10-11 years old. * Males: 11 - 12 years old. * Diagnosed with type-1 diabetes for at least 6 months. * Capacity to give informed consent (patient and parent/guardian). Children with the capacity to give assent will do so in addition to parental consent. Exclusion Criteria * Consuming any medications or have additional illnesses associated with bone health, osteoporosis (including renal disease, celiac disease, hypogonadism, hyperthyroidism) or altered physical growth (precocious puberty). * Have gone through adolescent growth spurt at study entry. Control Group (Typically Developing Children): Inclusion Criteria * Females: 10-11 years old. * Males: 11 - 12 years old. * Capacity to give informed consent (patient and parent/guardian). Children with the capacity to give assent will do so in addition to parental consent. Exclusion Criteria * Have an illness or are taking medications influencing bone health or physical growth. * Evidence of pathologic low trauma or vertebral fracture(s). * Have gone through adolescent growth spurt at study entry.
Where this trial is running
Saskatoon, Saskatchewan
- University of Saskatchewan — Saskatoon, Saskatchewan, Canada (Recruiting)
Study contacts
- Study coordinator: Saija Kontulainen, PhD
- Email: saija.kontulainen@usask.ca
- Phone: (306)966-1077
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.